J. Hall

Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan

D. Kiel, S. Cummings, O. Bruyère, 2022, Osteoporosis International.

Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan

D. Kiel, S. Cummings, O. Bruyère, 2022, Osteoporosis International.

Fracture incidence in a large cohort of men age 30 years and older with osteoporosis

C. O’Malley, P. Miller, U. Gruntmanis, 2015, Osteoporosis International.

Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate

C. Roux, J. Brown, C. Recknor, 2014, Osteoporosis International.

Previous fracture and subsequent fracture risk: A meta-analysis to update FRAX

D. Kiel, V. Gudnason, A. Díez-Pérez, 2023, Osteoporosis International.

A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.

J. Reginster, S. Boonen, A. Grauer, 2012, The Journal of clinical endocrinology and metabolism.